Scarica l'app Stockscreener
12.89
1.42%
0.18
Dopo l'orario di chiusura:
12.89
Precedente Chiudi:
$12.71
Aprire:
$12.91
Volume 24 ore:
72,690
Relative Volume:
0.62
Capitalizzazione di mercato:
$342.63M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-4.38%
1M Prestazione:
-3.73%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$12.25
$13.00
Intervallo di 1 settimana:
$12.25
$13.59
Portata 52W:
$11.81
$16.20
Carlsmed Inc Stock (CARL) Company Profile
Nome
Carlsmed Inc
Settore
Industria
Telefono
858-295-9290
Indirizzo
1800 ASTON AVENUE, CARLSBAD
Confronta CARL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CARL
Carlsmed Inc
|
12.89 | 337.85M | 0 | 0 | 0 | 0.00 |
|
VEEV
Veeva Systems Inc
|
291.20 | 46.72B | 2.97B | 809.93M | 1.33B | 4.8743 |
|
TEM
Tempus Ai Inc
|
89.85 | 14.99B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
66.00 | 12.33B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
94.58 | 8.01B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.85 | 7.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
Carlsmed Inc Stock (CARL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-18 | Iniziato | BTIG Research | Buy |
| 2025-08-18 | Iniziato | BofA Securities | Buy |
| 2025-08-18 | Iniziato | Goldman | Buy |
| 2025-08-18 | Iniziato | Piper Sandler | Overweight |
| 2025-08-18 | Iniziato | Truist | Buy |
Carlsmed Inc Borsa (CARL) Ultime notizie
Carlsmed Secures $60 Million Credit Facility Amendment - TipRanks
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025 | User | thepilotnews.com - FinancialContent
Carlsmed, Inc.Common Stock (Nasdaq:CARL) Stock Quote - FinancialContent
Carlsmed, Inc. (NASDAQ:CARL) Short Interest Update - MarketBeat
ETFs Investing in Carlsmed, Inc. Stocks - TradingView
AI medtech firm Carlsmed prices $100.5M IPO - MSN
Earnings Preview: Carlsmed to Report Financial Results Post-market on August 28 - 富途牛牛
Carlsmed appoints Jennifer Kamocsay as CLO, secretary - MSN
People moves: Michael Kaplan rejoins StandardAero as legal chief as Jenifer Kamocsay moves over to Carlsmed - | Governance Intelligence
Carlsmed names Jennifer Kamocsay as CLO and secretary - Medical Buyer
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - Orthopedics This Week
Carlsmed appoints Jenifer Kamocsay as chief legal officer By Investing.com - Investing.com Nigeria
Carlsmed appoints Jenifer Kamocsay as chief legal officer - Investing.com India
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - GlobeNewswire Inc.
Carlsmed, Inc. Selected for Inclusion in Russell 2000 Index - 富途牛牛
Carlsmed joins Russell 2000 Index following Q3 IPO - MSN
Carlsmed announces inclusion in Russell 2000 Index - TipRanks
Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index - MarketScreener
AI-Powered Spine Surgery Innovator Carlsmed Joins $9T Russell 2000 Index Following Successful IPO - Stock Titan
Carlsmed, Inc.(NasdaqGS: CARL) added to Russell 3000E Growth Benchmark - MarketScreener
AI medtech firm Carlsmed to sell 6.7M shares in IPO - MSN
Goldman Sachs highlights two high-potential stocks: AI marketing platform Braze (BRZE.US) and medical technology company Carlsmed (CARL.US), assigning them a 'Buy' rating. - 富途牛牛
Carlsmed initiated with Buy at Truist on business potential - MSN
Carlsmed Q2 2025 revenue up 99% to USD 12.1M - Medical Buyer
Carlsmed stock rating reiterated at Buy by Goldman Sachs on growth outlook - Investing.com Australia
Carlsmed, Inc.: Strong Financial Performance and Growth Potential Justify Buy Rating - TipRanks
Carlsmed, Inc.: Strong Performance and Promising Growth Prospects with Upcoming Product Launch - TipRanks
Carlsmed Reports Strong Growth in Q2 2025 Earnings - TipRanks
Carlsmed 2025 Q2 Earnings Strong Revenue Growth Despite Widening Net Loss - AInvest
Carlsmed: A High-Growth AI-Driven MedTech Play in Spine Surgery - AInvest
UPDATECarlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Earnings call transcript: Carlsmed’s Q2 2025 revenue surges, stock rises - Investing.com
Carlsmed Q2 Loss Narrows, Revenue Rises - MarketScreener
Carlsmed reports second quarter 2025 financial results - MarketScreener
Carlsmed® Q2 2025 Financial Performance: Assessing Long-Term Growth Potential in the AI-Driven Spine Surgery Revolution - AInvest
CARLSMED, INC. SEC 10-Q Report - TradingView
Carlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Carlsmed, Inc.'s Q2 2025 Performance and Strategic Momentum: A Disruptive Force in AI-Driven Spine Surgery - AInvest
99% Growth: AI Spine Surgery Pioneer Carlsmed Hits $12.1M Revenue, Expands into Cervical Procedures - Stock Titan
Carlsmed CARL 2025Q2 Earnings Preview Upside Potential on AI-Driven Spine Solutions - AInvest
Two AI Small Caps Nobody Noticed - Nanalyze
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Truist Securities initiates coverage on Carlsmed stock with Buy rating By Investing.com - Investing.com Australia
Why Is Carlsmed Stock Gaining Monday?Carlsmed (NASDAQ:CARL) - Benzinga
Carlsmed Inc Azioni (CARL) Dati Finanziari
Non sono disponibili dati finanziari per Carlsmed Inc (CARL). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
2.38%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):